These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
229 related articles for article (PubMed ID: 18826949)
1. Internal core protein cleavage leaves the hepatitis B virus capsid intact and enhances its capacity for surface display of heterologous whole chain proteins. Walker A; Skamel C; Vorreiter J; Nassal M J Biol Chem; 2008 Nov; 283(48):33508-15. PubMed ID: 18826949 [TBL] [Abstract][Full Text] [Related]
2. Development of hepatitis B virus capsids into a whole-chain protein antigen display platform: new particulate Lyme disease vaccines. Nassal M; Skamel C; Vogel M; Kratz PA; Stehle T; Wallich R; Simon MM Int J Med Microbiol; 2008 Jan; 298(1-2):135-42. PubMed ID: 17888729 [TBL] [Abstract][Full Text] [Related]
3. A fusion product of the complete Borrelia burgdorferi outer surface protein A (OspA) and the hepatitis B virus capsid protein is highly immunogenic and induces protective immunity similar to that seen with an effective lipidated OspA vaccine formula. Nassal M; Skamel C; Kratz PA; Wallich R; Stehle T; Simon MM Eur J Immunol; 2005 Feb; 35(2):655-65. PubMed ID: 15668917 [TBL] [Abstract][Full Text] [Related]
4. Displaying Whole-Chain Proteins on Hepatitis B Virus Capsid-Like Particles. Heger-Stevic J; Kolb P; Walker A; Nassal M Methods Mol Biol; 2018; 1776():503-531. PubMed ID: 29869263 [TBL] [Abstract][Full Text] [Related]
5. Hepatitis B virus capsid-like particles can display the complete, dimeric outer surface protein C and stimulate production of protective antibody responses against Borrelia burgdorferi infection. Skamel C; Ploss M; Böttcher B; Stehle T; Wallich R; Simon MM; Nassal M J Biol Chem; 2006 Jun; 281(25):17474-17481. PubMed ID: 16621801 [TBL] [Abstract][Full Text] [Related]
6. Whole-Chain Tick Saliva Proteins Presented on Hepatitis B Virus Capsid-Like Particles Induce High-Titered Antibodies with Neutralizing Potential. Kolb P; Wallich R; Nassal M PLoS One; 2015; 10(9):e0136180. PubMed ID: 26352137 [TBL] [Abstract][Full Text] [Related]
7. Structural identification of a key protective B-cell epitope in Lyme disease antigen OspA. Ding W; Huang X; Yang X; Dunn JJ; Luft BJ; Koide S; Lawson CL J Mol Biol; 2000 Oct; 302(5):1153-64. PubMed ID: 11183781 [TBL] [Abstract][Full Text] [Related]
8. Clonal diversification in OspA-specific antibodies from peripheral circulation of a chronic Lyme arthritis patient. Ghosh S; Huber BT J Immunol Methods; 2007 Apr; 321(1-2):121-34. PubMed ID: 17307198 [TBL] [Abstract][Full Text] [Related]
9. Structural and molecular analysis of a protective epitope of Lyme disease antigen OspA and antibody interactions. Shandilya S; Kurt Yilmaz N; Sadowski A; Monir E; Schiller ZA; Thomas WD; Klempner MS; Schiffer CA; Wang Y J Mol Recognit; 2017 May; 30(5):. PubMed ID: 27859766 [TBL] [Abstract][Full Text] [Related]
10. Broadly Protective Multivalent OspA Vaccine against Lyme Borreliosis, Developed Based on Surface Shaping of the C-Terminal Fragment. Nayak A; Schüler W; Seidel S; Gomez I; Meinke A; Comstedt P; Lundberg U Infect Immun; 2020 Mar; 88(4):. PubMed ID: 31932330 [TBL] [Abstract][Full Text] [Related]
11. Hepatitis B virus core and e antigen: immune recognition and use as a vaccine carrier moiety. Schödel F; Peterson D; Milich D Intervirology; 1996; 39(1-2):104-10. PubMed ID: 8957676 [TBL] [Abstract][Full Text] [Related]
12. Borrelia burgdorferi outer surface protein (osp) B expression independent of ospA. Liang FT; Caimano MJ; Radolf JD; Fikrig E Microb Pathog; 2004 Jul; 37(1):35-40. PubMed ID: 15194158 [TBL] [Abstract][Full Text] [Related]
13. Immunization with a recombinant subunit OspA vaccine markedly impacts the rate of newly acquired Borrelia burgdorferi infections in client-owned dogs living in a coastal community in Maine, USA. Eschner AK; Mugnai K Parasit Vectors; 2015 Feb; 8():92. PubMed ID: 25890386 [TBL] [Abstract][Full Text] [Related]
14. Borreliacidal OspC antibodies specific for a highly conserved epitope are immunodominant in human lyme disease and do not occur in mice or hamsters. Lovrich SD; Jobe DA; Schell RF; Callister SM Clin Diagn Lab Immunol; 2005 Jun; 12(6):746-51. PubMed ID: 15939749 [TBL] [Abstract][Full Text] [Related]
15. Quaternary structure is critical for protein display on capsid-like particles (CLPs): efficient generation of hepatitis B virus CLPs presenting monomeric but not dimeric and tetrameric fluorescent proteins. Vogel M; Vorreiter J; Nassal M Proteins; 2005 Feb; 58(2):478-88. PubMed ID: 15526302 [TBL] [Abstract][Full Text] [Related]
16. Immunogenicity of viral B-cell epitopes inserted into two surface loops of the Escherichia coli K12 LamB protein and expressed in an attenuated aroA strain of Salmonella typhimurium. Wang J; Michel V; Leclerc C; Hofnung M; Charbit A Vaccine; 1999 Jan; 17(1):1-12. PubMed ID: 10078601 [TBL] [Abstract][Full Text] [Related]
17. Molecular characterization of the OspA(161-175) T cell epitope associated with treatment-resistant Lyme arthritis: differences among the three pathogenic species of Borrelia burgdorferi sensu lato. Drouin EE; Glickstein LJ; Steere AC J Autoimmun; 2004 Nov; 23(3):281-92. PubMed ID: 15501399 [TBL] [Abstract][Full Text] [Related]
18. Structure-based design of a second-generation Lyme disease vaccine based on a C-terminal fragment of Borrelia burgdorferi OspA. Koide S; Yang X; Huang X; Dunn JJ; Luft BJ J Mol Biol; 2005 Jul; 350(2):290-9. PubMed ID: 15935380 [TBL] [Abstract][Full Text] [Related]
19. Hybrid hepatitis B virus core antigen as a vaccine carrier moiety: I. presentation of foreign epitopes. Schödel F; Peterson D; Hughes J; Wirtz R; Milich D J Biotechnol; 1996 Jan; 44(1-3):91-6. PubMed ID: 8717391 [TBL] [Abstract][Full Text] [Related]
20. Design and development of a novel vaccine for protection against Lyme borreliosis. Comstedt P; Hanner M; Schüler W; Meinke A; Lundberg U PLoS One; 2014; 9(11):e113294. PubMed ID: 25409015 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]